



Express Mail No.: EL 477 037 833 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Creation of: Busfield et al.

Confirmation No.: 6531

OCT 18 2002

Application No.: 09/503,387

Group Art Unit: 1644

TECH CENTER 1600/2900

Filed: February 14, 2000

Examiner: Huynh, P.

For: GLYCOPROTEIN VI AND USES  
THEREOF

Attorney Docket No.: 7853-178

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$1036.

The claim amendment fee has been estimated as shown below:

(Col 1)	(Col 2)	(Col 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY				
CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE	OR	RATE	ADDITIONAL FEE		
TOTAL	75	MINUS	47	28	* .9	\$	* 18	\$	504.00
INDEP.	9	MINUS	6	3	* .42	\$	* .84	\$	252.00
■ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				140	\$		280	\$	280.00
				TOTAL	\$	OR	TOTAL	\$	1036.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.  
A copy of this sheet is enclosed.

Respectfully submitted,

Date September 26, 2002

Laura A. Coruzzi 30.742  
Laura A. Coruzzi  
(Reg. No.)

By: Muna Abu-Shaar

Muna Abu-Shaar  
Limited Recognition Under 37 C.F.R. § 10.9(b)  
Copy of Certificate Enclosed

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosure



Express Mail No.: EL 477 037 833 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Busfield et al.

Confirmation No.: 6531

Application No.: 09/503,387

Group Art Unit: 1644

Filed: February 14, 2000

Examiner: Huynh, P.

For: GLYCOPROTEIN VI AND USES  
THEREOF

Attorney Docket No.: 7853-178

**TRANSMITTAL OF FORMAL DRAWINGS**

**Official Draftsperson**

c/o Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir/Madam:

In response to the Office Action March 26, 2002 and in connection with the above-identified patent application, transmitted herewith are formal drawings for the instant application. The formal drawings consist of FIGS. 1A through 19 (27 sheets of drawings).

Applicants respectfully request entry of the enclosed drawings into the file of the above-identified application.

Respectfully submitted,

Date September 26, 2002


Laura A. Coruzzi 30,742  
Laura A. Coruzzi (Reg. No.)

By: Muna Abu-Shaar

Muna Abu-Shaar  
Limited Recognition Under 37 C.F.R. § 10.9(b)  
Copy of Certificate Enclosed

**PENNIE & EDMONDS LLP**  
155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosures



Express Mail No.: EL 477 037 833 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Busfield et al.

Confirmation No.: 6531

Application No.: 09/503,387

Group Art Unit: 1644

Filed: February 14, 2000

Examiner: Huynh, P.

For: GLYCOPROTEIN VI AND USES  
THEREOF

Attorney Docket No.: 7853-178

**REQUEST FOR CORRECTED FILING RECEIPT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

SIR :

Applicants enclose herewith a copy of the Official Filing Receipt issued by the United States Patent and Trademark Office and a marked-up version with the corrections indicated in red ink. Specifically, the continuing data as claimed by Applicants is incomplete on the Filing Receipt. The continuing data recited on the Official Filing Receipt should reflect the priority under 35 U.S.C. § 120 claimed by Applicants in the executed Declarations and Powers of Attorney filed on June 1, 2000 in response to the Notice To File Missing Parts of Nonprovisional Application. Specifically, the continuing data as claimed by Applicants should recite that the above-identified application is a continuation-in-part of U.S. application Serial No. 09/454,824, filed December 6, 1999, which is a continuation-in-part of U.S. application Serial No. 09/345,648, filed June 30, 1999.

Applicants respectfully request that the United States Patent and Trademark Office correct its records and issue a corrected Filing Receipt with the complete continuing data claimed by Applicants.

Applicants further request that the corrected Filing Receipt reflects the amended inventorship in view of the Petition to Amend Inventorship Under 37 C.F.R. § 1.48(b) submitted concurrently herewith. In particular, Applicants request that the corrected Filing Receipt reflect the removal of Martine Jandrot-Perrus and William Vainchencker as co-inventors of the present application, thereby naming only Samantha J. Busfield and Jean-Luc Villeval as inventors.

It is estimated that no fee is required for correction of the Filing Receipt. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date September 26, 2002

Laura A. Coruzzi 30,742  
Laura A. Coruzzi (Reg. No.)

By: Muna Abu Shaar  
Muna Abu-Shaar  
Limited Recognition Under 37 C.F.R. § 10.9(b)  
Copy of Certificate Enclosed

**PENNIE & EDMONDS LLP**  
155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosures



## FILING RECEIPT



\*OC00000005031869\*

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND  
COMMISSIONER OF PATENT AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/503,387	02/14/2000	1646	744	7853-178	30	23	3

20583  
 PENNIE AND EDMONDS  
 1155 AVENUE OF THE AMERICAS  
 NEW YORK, NY 100362711

REC'D 4/4/01  
 APR 11 2000  
 CJK 2000-04-01

Date Mailed: 04/05/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Samantha J. Busfield, Cambridge, MA ;  
 Jean-Luc Villevan, Needham, MA ;  
 Martine Jandrot-Perrus, Vanes, FRANCE;  
 William Vainchencker, Paris, FRANCE;

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/345,468 06/30/1999

## Foreign Applications

If Required, Foreign Filing License Granted 04/05/2000

\*\*

## Title

Glycoprotein VI and uses thereof ✓

REFERRED TO	Chetka
REC'D	
APR 11 2000	
Pennie & Edmunds	
O.K. for filing	

## Preliminary Class

435

Data entry by : ZIMMERMAN, SHAUNA

Team : OIPE

Date: 04/05/2000



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "**new**," "**improved**," "**improvements in**" or "**relating to**" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
 Office of Initial Patent Examination  
 Customer Service Center  
 Washington, DC 20231